TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06255262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: (1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
Study: NCT05222295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Pulmonary Telerehabilitation
Description: For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
Study: NCT00888680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC20-1531
Description: BGC20-1531 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC20-1531
Description: BGC20-1531 administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Placebo administered orally
Study: NCT05234853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR001
Description: Monoclonal antibody
Study: NCT06192667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GC Geanial Injectable (Tokyo,Japan)
Description: Highly filled composite resin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Filtek Z250 Universal Restorative (Germany)
Description: Conventional composite resin
Study: NCT05343741

Intervention type: OTHER
Intervention: Psychological Intervention
Description: The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
Study: NCT05286996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iovera - Cryoneurolysis
Description: Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local anesthetic
Description: Placebo - local anaesthesia
Study: NCT04814407

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-derived DNA methylation detection
Description: Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-derived DNA methylation detection
Description: Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-derived DNA methylation detection
Description: Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
Study: NCT06145087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NOVOS Core supplement
Description: The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
Study: NCT05915546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablets
Study: NCT05045859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT for PTSD
Description: CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
Study: NCT06524271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Soybean
Description: Same as described earlier

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement without fermented soybean
Description: Same as described earlier
Study: NCT06426498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsonix Bx Pulsar machine tFUS
Description: This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
Study: NCT06009822

Intervention type: OTHER
Intervention: Postoperative outcome measurements
Description: Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index.
Study: NCT06198062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin wax bath therapy
Description: this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin Wax Bath Therapy and Muscle Energy Techniques
Description: This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
Study: NCT06305585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primal Reflex Release Technique (PRRT)
Description: Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
Study: NCT05608954

Intervention type: OTHER
Intervention: Bobath Concept
Description: Handling of the Bobath Concept

Intervention type: OTHER
Intervention: Pediasuit
Description: Pediasuit

Intervention type: OTHER
Intervention: Locomotor training
Description: Locomotor training

Intervention type: OTHER
Intervention: Stretching
Description: Active, passive, active-assisted stretching

Intervention type: OTHER
Intervention: Psychomotricity
Description: Psychomotor skills

Intervention type: OTHER
Intervention: Virtual reality
Description: Virtual reality
Study: NCT06221410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative teaching method: Funny Scenario-Based Education
Description: A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative teaching method: Mind-mapping Education
Description: As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
Study: NCT06226597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit device
Description: Daily use of a fitbit wearable activity tracker device.
Study: NCT05706207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study: NCT05173012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-324 Matched Placebo
Description: SAGE-324 matched placebo oral tablets.
Study: NCT04645511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon sinuplasty of maxillary sinuses
Description: A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
Study: NCT04821947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine
Description: for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine
Study: NCT04645511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon sinuplasty of maxillary sinuses
Description: A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Description: The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Description: The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides.
Study: NCT04998500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth hormone, saline and GH receptor blockade (Pegvisomant)
Description: This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth hormone, saline and GH receptor blockade (Pegvisomant)
Description: This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
Study: NCT05738954

Intervention type: OTHER
Intervention: Ultrasound
Description: Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion.
Study: NCT04850937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
Study: NCT05518019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The Daily Supplement
Description: Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol
Study: NCT05922007

Intervention type: OTHER
Intervention: Validation of the Questionnaire
Description: Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)

Intervention type: OTHER
Intervention: Prospective quantitative study - questionnaire survey
Description: A questionnaire survey will be carried out using the questionnaire set three times
Study: NCT04263766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
Study: NCT06362577

Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG
Description: Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG
Description: Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
Study: NCT05431192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training + Enhanced Usual Care
Description: Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study.
Study: NCT06453343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach: cochleostomy or extended round window
Description: Surgical placement of a cochlear implant electrode array

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach: cochleostomy or extended round window
Description: Surgical placement of a cochlear implant electrode array
Study: NCT06481020

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols 2g/day
Description: PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet containing the powdered excipients of the dietary supplement during 8 weeks
Study: NCT05823870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6014
Description: Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6014
Description: Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast
Study: NCT04310865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinhu Qingwen Granula
Description: Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yin Hu Qing Wen Granula(low does)
Description: This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical treatment
Description: Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard medical treatment
Description: Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
Study: NCT05142163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative SVV Guided Fluid Therapy
Description: Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative PVI Guided Fluid Therapy
Description: Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.